Publicaciones en las que colabora con María Consuelo López-Berges (29)

2011

  1. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    Blood, Vol. 117, Núm. 13, pp. 3613-3616

2010

  1. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders

    Cytometry Part B - Clinical Cytometry, Vol. 78, Núm. 4, pp. 239-252

2009

  1. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

    Blood, Vol. 114, Núm. 20, pp. 4369-4372

2008

  1. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

    Blood, Vol. 112, Núm. 10, pp. 4017-4023

2005

  1. Cell cycle analysis of Waldenström's macroglobulinemia

    Clinical Lymphoma, Vol. 5, Núm. 4, pp. 250-252

  2. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells

    Haematologica, Vol. 90, Núm. 1, pp. 54-59

2004

  1. CD34 + cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance - Associated phenotypes

    Clinical Cancer Research, Vol. 10, Núm. 22, pp. 7599-7606

  2. Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34- bone marrow cell compartments from patients with myelodysplastic syndromes [3]

    Leukemia

2003

  1. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: Early immunophenotypic evaluation has high clinical value

    Blood, Vol. 101, Núm. 12, pp. 4695-4700

2002

  1. Incidence of phenotypic aberrations in series of 467 patients with B chronic lymphoproliferative disorders: Basis for the design of specific four-color stainings to be used for minimal residual disease investigation

    Leukemia, Vol. 16, Núm. 8, pp. 1460-1469

1999

  1. An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia

    Communications in Clinical Cytometry, Vol. 38, Núm. 2, pp. 70-75

1998

  1. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: Implications for minimal residual disease detection

    Haematologica, Vol. 83, Núm. 12, pp. 1069-1075

  2. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia

    Journal of Clinical Oncology, Vol. 16, Núm. 12, pp. 3774-3781

1997

  1. Controversias en la determinación de CD34

    Sangre, Vol. 42, Núm. SUPPL. 1

  2. Controversies in the determination of CD34

    Sangre, Vol. 42 Suppl 1, pp. 7-9

1996

  1. Phenotypic changes in acute myeloid leukaemia: Implications in the detection of minimal residual disease

    Journal of Clinical Pathology, Vol. 49, Núm. 1, pp. 15-18

  2. The immunology laboratory in malignant blood diseases

    Sangre, Vol. 41, Núm. 4, pp. 281-288

1995

  1. Characterization of aberrant phenotypes in acute myeloblastic leukemia

    Annals of Hematology, Vol. 70, Núm. 4, pp. 189-194

  2. DNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markers

    Cytometry, Vol. 22, Núm. 1, pp. 22-25

  3. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: Implications for minimal residual disease studies

    Leukemia, Vol. 9, Núm. 6, pp. 993-998